Other OTC - Delayed Quote USD

Roche Holding AG (RHHBY)

31.24 +0.33 (+1.07%)
At close: April 23 at 3:59 PM EDT
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
60,441,000.00
60,441,000.00
65,814,000.00
62,801,000.00
58,323,000.00
Cost of Revenue
16,357,000.00
16,357,000.00
19,737,000.00
19,647,000.00
16,177,000.00
Gross Profit
44,084,000.00
44,084,000.00
46,077,000.00
43,154,000.00
42,146,000.00
Operating Expense
28,689,000.00
28,689,000.00
28,601,000.00
24,999,000.00
23,603,000.00
Operating Income
15,395,000.00
15,395,000.00
17,476,000.00
18,155,000.00
18,543,000.00
Net Non Operating Interest Income Expense
-814,000.00
-814,000.00
-673,000.00
-414,000.00
-528,000.00
Pretax Income
14,079,000.00
14,079,000.00
16,327,000.00
17,398,000.00
17,965,000.00
Tax Provision
1,721,000.00
1,721,000.00
2,796,000.00
2,463,000.00
2,897,000.00
Net Income Common Stockholders
11,498,000.00
11,498,000.00
12,421,000.00
13,930,000.00
14,295,000.00
Average Dilution Earnings
--
--
-1,000.00
-1,000.00
-1,000.00
Diluted NI Available to Com Stockholders
11,498,000.00
11,498,000.00
12,420,000.00
13,929,000.00
14,294,000.00
Basic EPS
1.80
--
1.94
2.05
2.09
Diluted EPS
1.79
--
1.92
2.02
2.06
Basic Average Shares
6,392,000.00
--
6,400,000.00
6,800,000.00
6,840,000.00
Diluted Average Shares
6,432,000.00
--
6,464,000.00
6,880,000.00
6,920,000.00
Total Operating Income as Reported
15,395,000.00
15,395,000.00
17,476,000.00
18,155,000.00
18,543,000.00
Total Expenses
45,046,000.00
45,046,000.00
48,338,000.00
44,646,000.00
39,780,000.00
Net Income from Continuing & Discontinued Operation
11,498,000.00
11,498,000.00
12,421,000.00
13,930,000.00
14,295,000.00
Normalized Income
11,600,726.00
11,600,726.00
12,972,285.00
14,446,516.00
13,812,575.00
Interest Income
195,000.00
195,000.00
67,000.00
--
16,000.00
Interest Expense
997,000.00
997,000.00
690,000.00
419,000.00
553,000.00
Net Interest Income
-814,000.00
-814,000.00
-673,000.00
-414,000.00
-528,000.00
EBIT
15,076,000.00
15,076,000.00
17,017,000.00
17,817,000.00
18,518,000.00
EBITDA
18,540,000.00
18,540,000.00
20,861,000.00
22,260,000.00
23,076,000.00
Reconciled Cost of Revenue
16,357,000.00
16,357,000.00
19,737,000.00
19,647,000.00
16,177,000.00
Reconciled Depreciation
3,464,000.00
3,464,000.00
3,844,000.00
4,443,000.00
4,558,000.00
Net Income from Continuing Operation Net Minority Interest
11,498,000.00
11,498,000.00
12,421,000.00
13,930,000.00
14,295,000.00
Total Unusual Items Excluding Goodwill
-117,000.00
-117,000.00
-665,000.00
-602,000.00
575,000.00
Total Unusual Items
-117,000.00
-117,000.00
-665,000.00
-602,000.00
575,000.00
Normalized EBITDA
18,657,000.00
18,657,000.00
21,526,000.00
22,862,000.00
22,501,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-14,274.00
-14,274.00
-113,715.00
-85,484.00
92,575.00
12/31/2020 - 8/20/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SNY Sanofi
47.69
+1.15%
 
NVS Novartis AG
97.28
+2.27%
 
GSK GSK plc
41.24
+1.60%
 
BAYRY Bayer Aktiengesellschaft
7.37
+0.20%
 
AZN AstraZeneca PLC
70.85
+1.03%
 
BMY Bristol-Myers Squibb Company
48.99
-0.31%
 
GILD Gilead Sciences, Inc.
67.03
+0.12%
 
BIIB Biogen Inc.
193.18
-0.48%
 
MRK Merck & Co., Inc.
126.88
-0.05%
 
AMGN Amgen Inc.
273.54
+0.60%